---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-266101"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2024-11-26T23:59:59+00:00"
generated_at: "2026-05-29T18:00:34.338880+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Hans Bishop resigns from Lyell Immunopharma Board and Nominating Committee

## Summary
- Hans Bishop resigned from the Board and Nominating Committee effective November 22, 2024.
- Resignation is not the result of any disagreement or dispute with the Company.
- No replacement has been announced; board composition changes accordingly.

## SEC filing metadata
- accession: 0001193125-24-266101
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2024-11-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000119312524266101/0001193125-24-266101-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000119312524266101/d848587d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-266101
- JSON: https://secwatch.observer/filing/0001193125-24-266101.json
- Plain text: https://secwatch.observer/filing/0001193125-24-266101.txt

## Key facts
- Executive change
  Hans Bishop resigned as Director at Lyell Immunopharma, Inc..
  - Action: resigned
  - Role: Director
  source text: On November 22, 2024, Hans Bishop resigned as a member of the Board of Directors (the “Board”) and the Nominating and Corporate Governance Committee of the Board of Lyell Immunopharma, Inc. (the “Company”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806952/000119312524266101/0001193125-24-266101-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.